We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Home CompaniesVivos Inc

Vivos Inc

Healthcare Medical Devices
PortfolioPortfolio WatchlistWatchlist
Company price
0.044 USD -0.00 ( 0.23%)
Last update at 2026-11-12T15:40:00Z
VOLUME
11510
Market Cap
26.09M

Momentum Score

…

Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States and internationally. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.04
Low
0.04
High
52 Week Price Range
0.04
Low
0.12
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Vivos Inc, quoted RDGL on the OTCQB, does not have a clear, independently verifiable public description of its core business in widely available filings. Long-term growth may therefore depend on management executing any stated strategy, securing partnerships or customers, and improving disclosure and financial reporting, which could support investor interest if progress is demonstrable.

Risk Score
Low

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.04
Dividend Yield
0.81%
Revenue TTM
0.03M
Revenue Per Share
-
Gross Profit TTM
0.01M
Debt / Equity
-
ROE
-150.95%
Net Debt
0.77M
ROCE
-151.58%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -2.47M -2.53M -0.96M -1.61M -7.70M
Net income -2.47M -2.53M -0.96M -1.61M -7.70M
Selling general administrative 2.18M 2.22M 0.59M 1.27M 2.39M
Gross profit 0.01M 0.00M 0.00M 0.00M 0.00M
Reconciled depreciation - - - - 0.00M
Ebit -2.52M -2.50M -0.67M -1.33M -2.49M
Ebitda -2.47M -2.50M -0.67M -1.35M -2.05M
Operating income -2.52M -2.50M -0.67M -1.33M -2.47M
Interest expense 0.00M 0.03M 0.29M 0.26M 5.65M
Tax provision 0.00M 0.00M 0.00M 0.00M 0.00M
Net interest income 0.00M -0.03M -0.29M -0.26M -5.65M
Income tax expense - - - - 0.00M
Total revenue 0.04M 0.01M 0.01M 0.01M 0.00M
Total operating expenses 2.55M 2.52M 0.68M 1.34M 2.47M
Cost of revenue 0.03M 0.01M 0.01M 0.01M 0.00M
Total other income expense net 0.05M -0.00M 0.00M -0.02M 0.42M
Net income from continuing ops -2.47M -2.53M -0.96M -1.61M -7.70M
Net income applicable to common shares -2.47M -2.53M -0.96M -1.61M -7.70M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Total assets 1.74M 1.63M 0.94M 0.04M 0.02M
Total liab 0.08M 0.17M 0.91M 1.52M 0.96M
Total stockholder equity 1.66M 1.47M 0.03M -1.48M -0.94M
Other current liab - - 0.03M 0.03M 0.04M
Common stock 0.36M 0.34M 0.29M 0.18M 0.16M
Capital stock 0.37M 0.35M 0.30M 0.19M 1.31M
Retained earnings -79.56M -77.09M -74.56M -73.60M -71.99M
Cash 1.71M 1.61M 0.90M 0.02M 0.01M
Total current liabilities 0.08M 0.17M 0.91M 1.52M 0.96M
Net debt - - - 0.77M 0.05M
Short term debt - - - - 0.05M
Short long term debt - - 0.34M 0.79M 0.05M
Total current assets 1.74M 1.63M 0.94M 0.04M 0.02M
Net tangible assets -7.98M -8.17M -9.71M -11.69M -11.70M
Net receivables 0.01M - - - -
Accounts payable 0.08M 0.17M 0.36M 0.51M 0.80M
Non currrent assets other - - - 0.00M 0.00M
Non current assets total 0.00M 0.00M 0.00M 0.00M 0.00M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments - - - - 0.00M
Change to liabilities 0.01M 0.03M -0.15M -0.14M -0.13M
Net borrowings - -0.14M 0.10M 0.75M -0.04M
Total cash from financing activities 1.22M 1.67M 1.76M 0.85M 0.70M
Change to operating activities 0.00M -0.09M -0.01M 0.11M 0.68M
Net income -2.47M -2.53M -0.96M -1.61M -7.70M
Change in cash 0.10M 0.70M 0.88M 0.01M -0.00M
Begin period cash flow 1.61M 0.90M 0.02M 0.01M 0.01M
End period cash flow 1.71M 1.61M 0.90M 0.02M 0.01M
Total cash from operating activities -1.12M -0.96M -0.88M -0.84M -0.70M
Issuance of capital stock 1.22M 1.81M 1.66M 0.10M 0.74M
Depreciation - - - - 0.00M
Change to account receivables -0.01M -0.01M -0.01M -0.01M -
Sale purchase of stock - 0.00M -0.06M - -
Other cashflows from financing activities - 0.01M 0.01M 0.01M 0.01M
Change to netincome 1.35M 1.62M 0.18M 0.62M 5.66M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.00M -0.05M -0.16M -0.03M 0.55M
Stock based compensation - - 0.00M 0.61M -
Other non cash items 1.35M 1.62M 0.24M 0.84M 2.23M
Free cash flow -1.12M -0.96M -0.88M -0.84M -0.70M

Peer Comparison*

Sector: Healthcare Industry: Medical Devices

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
RDGL
Vivos Inc		 -0.00
0.23%		 0.04 - - 1125.87 20.10 1066.86 -11.06
ABT
Abbott Laboratories		 -0.71
0.65%		 108.58 25.97 17.24 3.57 3.20 3.81 16.75
MDT
Medtronic PLC		 0.28
0.28%		 101.89 26.60 15.87 3.35 2.08 3.90 14.12
SYK
Stryker Corporation		 -2.16
0.68%		 316.63 29.23 16.86 4.18 4.51 4.63 17.16
SEMHF
Siemens Healthineers AG		 -
-%		 47.31 39.57 21.32 3.01 3.29 2.95 16.92

Profile*

Vivos Inc

Vivos Inc., a radiation oncology medical device company, develops brachytherapy devices for the treatment of non-resectable tumors in the United States and internationally. It develops yttrium-90 based RadioGel device, an injectable particle-gel for brachytherapy radiation treatment of cancerous tumors in people and animals; and IsoPet for the treatment of solid tumors in animals. The company was formerly known as Advanced Medical Isotope Corporation and changed its name to Vivos Inc. in December 2017. Vivos Inc. was incorporated in 1994 and is headquartered in Richland, Washington.

719 Jadwin Avenue, Richland, WA, United States, 99352

509 736 4000

https://www.radiogel.com

1

Name Title Year Born
Dr. Michael K. Korenko Ph.D. CEO, Pres & Director 1946
Dr. Carlton M. Cadwell D.D.S. Independent Chairman & Sec. 1945
Mr. Michael H. Pollack CPA, CPA Chief Financial Officer 1966
Dr. David J. Swanberg M.S., P.E. Chief Technical Mang. 1957
Dr. Nigel R. Stevenson B.Sc., Ph.D. Chief Science Officer NA
Dr. Fu-Min Su Chief Radio Chemist & Radiation Safety Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

PARA
USD 0.10
+38.58%
LUNR
USD 13.91
+14.20%
MBGL
USD 22.63
+13.60%
FRMI
USD 2.04
+12.71%
FIGR
USD 26.97
+11.49%
CDNL
USD 6.09
-59.37%
ADIG
USD 11.79
-39.79%
CTVA
USD 9.21
-24.11%
BZ
USD 12.99
-22.28%
ENVX
USD 1.98
-21.70%

Equity Sectors*

  • Basic Materials

    -1.40%

  • Communication Services

    -0.45%

  • Consumer Cyclical

    -0.55%

  • Consumer Defensive

    -0.01%

  • Energy

    -0.01%

  • Financial Services

    -0.40%

  • Financials

    -0.15%

  • Healthcare

    -1.15%

  • Industrials

    -0.46%

  • Real Estate

    -0.29%

  • Technology

    -1.22%

  • Utilities

    -0.10%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…